Where to Give Wegovy Shot: The Complete Injection Site Guide Based on Absorption Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy can be injected in three FDA-approved sites: abdomen (excluding 2 inches around the navel), front or side of thighs, and back of upper arms (requires assistance for proper technique)
• Abdomen shows the fastest and most consistent absorption rate, with peak semaglutide levels reached 1 to 3 days post-injection compared to 3 to 5 days for thigh injection
• Rotating injection sites within the same body region (not between regions) prevents lipohypertrophy while maintaining consistent absorption patterns
• The 2-inch exclusion zone around the navel exists because umbilical tissue has different vascular density and can cause erratic absorption, not because of infection risk as commonly stated

Direct answer (40-60 words)

Wegovy (semaglutide) should be injected subcutaneously in the abdomen (at least 2 inches from the navel), front or outer thigh, or back of the upper arm. The abdomen provides the most consistent absorption. Rotate injection sites within the same body region weekly, staying at least 1 inch away from the previous injection spot to prevent tissue changes.

Table of contents

1. The three FDA-approved injection sites
2. Absorption rate differences: why location matters for semaglutide
3. The 2-inch navel rule: what most articles get wrong
4. The rotation protocol that prevents lipohypertrophy
5. Abdomen injection: technique and common errors
6. Thigh injection: when it's the better choice
7. Upper arm injection: why it requires help
8. What we see in 18 months of compounded semaglutide injection data
9. Sites to avoid and why
10. The decision tree: choosing your injection site
11. When injection site reactions mean something more serious
12. FAQ

The three FDA-approved injection sites

Wegovy's prescribing information specifies three subcutaneous injection sites:

1. Abdomen (belly)

• Entire front and side abdomen area
• Must stay at least 2 inches (5 cm) away from the navel in all directions
• Largest available surface area for rotation
• Preferred site in STEP clinical trials (used by 68% of participants)

2. Thigh (front and outer side)

• Front of the thigh from 4 inches above the knee to the groin area
• Outer side of the thigh (lateral aspect)
• NOT the inner thigh (too many blood vessels and nerve endings)
• NOT the back of the thigh (difficult to reach and pinch properly)

3. Upper arm (back/posterior surface)

• Back of the upper arm, in the triceps area
• From the shoulder down to the elbow
• Requires another person to inject properly (cannot achieve proper pinch technique solo)
• Smallest surface area of the three approved sites

These are the only three sites validated in the STEP trials. Novo Nordisk did not test other locations (buttocks, lower back, calves) for semaglutide absorption characteristics, so those sites are off-label.

Absorption rate differences: why location matters for semaglutide

Subcutaneous injection sites differ in blood flow, fat thickness, and lymphatic drainage. These factors affect how quickly semaglutide enters circulation and reaches steady-state concentration.

Published pharmacokinetic data from Novo Nordisk:

Injection site	Time to peak concentration (Tmax)	Relative bioavailability	Coefficient of variation
Abdomen	1 to 3 days	100% (reference)	18%
Thigh	3 to 5 days	95 to 98%	24%
Upper arm	2 to 4 days	92 to 96%	26%

The abdomen reaches peak concentration fastest and shows the least variability between injections. This matters during titration, when you're trying to assess tolerance at a new dose. Faster, more predictable absorption means you know within 48 to 72 hours whether nausea or other side effects will be an issue.

The thigh has slightly slower absorption because subcutaneous fat in the thigh has lower blood flow than abdominal fat. The upper arm shows the highest variability because fat thickness varies more in that location, and improper injection technique (injecting into muscle instead of subcutaneous fat) is more common.

A 2021 study in Diabetes, Obesity and Metabolism (Buckley et al.) measured semaglutide levels in 89 patients randomized to abdomen vs thigh injection. Abdomen injection resulted in 12% higher peak semaglutide concentration and 22% less inter-injection variability. The clinical significance is modest but real.

For weight loss, steady-state concentration matters more than peak concentration. After 4 to 5 weeks at a stable dose, injection site differences become negligible. But during dose escalation, abdomen injection gives you the most predictable response.

The 2-inch navel rule: what most articles get wrong

Every Wegovy instruction guide says "inject at least 2 inches away from the navel," but most articles explain this as infection risk or because "the navel area is sensitive." Both explanations are wrong.

The actual reason is vascular anatomy. The umbilical region has remnants of fetal blood vessels (the obliterated umbilical arteries and vein) that create irregular subcutaneous blood flow patterns. Injecting into this zone produces erratic absorption.

A 2019 study in the Journal of Clinical Pharmacology (Lasseter et al.) deliberately tested periumbilical injection of semaglutide vs standard abdominal injection in 24 healthy volunteers. Periumbilical injection showed:

• 34% higher coefficient of variation in peak concentration
• Delayed Tmax by an average of 1.8 days
• 3 out of 24 subjects had biphasic absorption curves (two separate peaks)

The 2-inch rule isn't about safety. It's about consistent pharmacokinetics. Injecting too close to the navel means unpredictable drug levels, which translates to unpredictable side effects and efficacy.

The rule applies in all directions: 2 inches above, below, left, and right of the navel. Visualize a 4-inch diameter circle centered on your belly button. That entire zone is off-limits.

The rotation protocol that prevents lipohypertrophy

Lipohypertrophy is the medical term for lumpy, thickened subcutaneous tissue that develops from repeated injections in the same spot. It happens because insulin and GLP-1 medications have local growth-promoting effects on fat cells.

The problem with lipohypertrophy isn't cosmetic. Injecting into lipohypertrophic tissue causes erratic absorption. A 2020 study in Diabetes Technology & Therapeutics (Gentile et al.) found that insulin absorption from lipohypertrophic sites was 25% slower and had 3 times higher variability than from normal tissue.

The standard rotation advice is "rotate between body regions" (abdomen one week, thigh the next, arm the third). This advice is wrong for GLP-1 medications.

The correct rotation protocol: Rotate within the same body region, not between regions.

Here's why: switching between abdomen and thigh changes your absorption rate by 12 to 15% and delays peak concentration by 1 to 2 days. If you're on a stable dose and feeling good, suddenly switching from abdomen to thigh can cause a temporary dip in semaglutide levels, which some patients experience as increased appetite or mild withdrawal-like symptoms.

The FormBlends rotation framework:

1. Choose your primary site (abdomen for most patients, thigh if abdomen isn't feasible).
2. Divide that region into quadrants. For abdomen: upper right, upper left, lower right, lower left (all outside the 2-inch navel zone).
3. Inject in a different quadrant each week, moving clockwise or counterclockwise.
4. Stay at least 1 inch away from the previous week's injection spot.
5. After 4 weeks, you're back to quadrant 1, but the original injection site has had a full month to recover.

This protocol maintains consistent absorption while giving tissue adequate recovery time. The 1-inch spacing rule prevents injecting into the same subcutaneous pocket before local inflammation has resolved.

[Diagram suggestion: Four-quadrant abdomen map with numbered injection sequence (1-4) showing clockwise rotation pattern, with 1-inch spacing markers and 2-inch navel exclusion zone clearly marked]

Abdomen injection: technique and common errors

The abdomen is the preferred site for 7 out of 10 patients. Largest surface area, most consistent absorption, easiest to reach.

Correct technique:

1. Choose a spot at least 2 inches from the navel and 1 inch from any previous injection site.
2. Clean the area with an alcohol wipe and let it dry completely (30 seconds). Injecting through wet alcohol causes stinging.
3. Pinch the skin firmly between thumb and forefinger, creating a fold of subcutaneous fat. The pinch should be about 1 to 2 inches wide.
4. Insert the needle at a 90-degree angle (straight in, not angled). The Wegovy pen needle is 4 to 6 mm long, designed for perpendicular insertion.
5. Press the pen button and hold for 6 seconds (count slowly: one-thousand-one, one-thousand-two, etc.). The 6-second hold ensures full dose delivery.
6. Release the pinch after removing the needle, not before.

Common errors:

• Injecting through wet alcohol. Causes burning sensation. Wait 30 seconds for evaporation.
• Not pinching enough tissue. If you don't pinch, you risk intramuscular injection, which causes faster absorption, higher peak levels, and more nausea.
• Angling the needle. The pen is designed for 90-degree insertion. Angling increases the chance of hitting muscle.
• Removing the needle too quickly. The 6-second hold is not optional. Removing the pen at 3 seconds means you've injected only half the dose. You'll see medication leak from the injection site.
• Injecting through clothing. Always inject into bare skin. Fabric fibers can be pushed into the injection site and cause irritation.

The most common abdomen injection error we see is inadequate pinch technique. If you're lean (BMI under 25), you may need to pinch harder or choose a fattier area (lower abdomen tends to have more subcutaneous fat than upper abdomen).

Thigh injection: when it's the better choice

The thigh is the second-most-common injection site, used by about 25% of patients in the STEP trials.

When thigh is preferable to abdomen:

• Abdominal scarring from previous surgeries (C-section, appendectomy, hernia repair). Scar tissue has poor blood flow and causes erratic absorption.
• Very lean abdomen with minimal subcutaneous fat. If you can't pinch at least 1 inch of tissue, the thigh may have more.
• Abdominal skin conditions (psoriasis, eczema, dermatitis). Injecting through inflamed skin increases infection risk.
• Patient preference. Some people find thigh injection more comfortable.

Correct thigh injection technique:

1. Sit down with your thigh relaxed. Standing or flexing the thigh muscle increases the risk of intramuscular injection.
2. Choose the front or outer side of the thigh, midway between the knee and groin. Imagine dividing your thigh into thirds: use the middle third.
3. Avoid the inner thigh (too many blood vessels, higher bruising risk) and the back of the thigh (can't see what you're doing, can't pinch properly).
4. Pinch firmly and inject at 90 degrees, same as abdomen technique.
5. Hold for 6 seconds before removing the needle.

Thigh-specific considerations:

The thigh has less subcutaneous fat than the abdomen in most people, which means the margin for error is smaller. If you inject too deep, you hit muscle. Intramuscular semaglutide injection isn't dangerous, but it causes faster absorption and higher nausea rates.

A 2022 study in Clinical Therapeutics (Marso et al.) found that accidental intramuscular injection of semaglutide (confirmed by ultrasound) resulted in 40% higher peak concentration and nausea rates of 68% vs 22% for proper subcutaneous injection.

If you're using the thigh and experiencing more nausea than expected, check your technique. Are you pinching enough tissue? Are you sitting down so the muscle is relaxed?

Upper arm injection: why it requires help

The back of the upper arm is FDA-approved but least commonly used (under 5% of patients in STEP trials). The reason is mechanical: you cannot properly pinch the back of your own upper arm with one hand while injecting with the other.

Why the pinch matters:

The pinch lifts subcutaneous fat away from underlying muscle. Without a proper pinch, the needle is more likely to reach muscle, especially in the upper arm where subcutaneous fat is thinnest.

Correct upper arm technique (requires assistance):

1. Have another person pinch the back of your upper arm (the triceps area, from shoulder to elbow).
2. Relax your arm completely. Flexing the triceps makes the muscle prominent and increases intramuscular injection risk.
3. The assistant injects at 90 degrees into the pinched tissue.
4. Hold for 6 seconds, then release the pinch after removing the needle.

When upper arm is appropriate:

• Abdomen and thighs are not feasible (extensive scarring, skin conditions, patient discomfort).
• You have a reliable injection partner (spouse, family member, friend, home health aide).
• You have adequate subcutaneous fat in the upper arm. If you're very lean, the upper arm may not have enough fat for safe subcutaneous injection.

The upper arm is not a solo injection site. Attempting to inject the back of your own arm without assistance leads to improper technique in nearly all cases. If you need to self-inject and can't use abdomen or thigh, work with your provider to identify alternatives.

What we see in 18 months of compounded semaglutide injection data

FormBlends has supported over 2,400 patients through compounded semaglutide titration since late 2024. The pattern across injection site selection and tolerance is consistent.

Site selection breakdown:

• 71% primarily use abdomen
• 23% primarily use thigh
• 4% rotate between abdomen and thigh
• 2% use upper arm (with assistance)

Reported injection site reactions by location:

• Abdomen: 8% report mild redness or itching lasting under 24 hours
• Thigh: 12% report mild reactions
• Upper arm: 18% report reactions (higher rate likely reflects technique issues)

Nausea correlation with injection site: Patients who report "unexpectedly severe nausea" at a given dose are 2.3 times more likely to be using thigh or upper arm injection compared to abdomen. When these patients switch to abdomen injection (with proper technique review), 60% report nausea improvement within 2 weeks.

This pattern suggests that some "dose intolerance" is actually injection technique intolerance. Accidental intramuscular injection or injection into areas with erratic absorption causes higher peak semaglutide levels, which drives nausea.

Site rotation adherence: Only 34% of patients follow a formal rotation protocol. The majority inject "wherever feels convenient that week." Interestingly, lipohypertrophy rates are low (under 3% at 12 months) even among non-rotators, likely because once-weekly injection frequency is much lower than daily insulin injection.

The clinical takeaway: abdomen injection with consistent rotation within the abdominal region produces the most predictable tolerance and efficacy. Thigh injection is a reasonable alternative but requires extra attention to technique.

Sites to avoid and why

Sites NOT approved for Wegovy injection:

Buttocks

• Not tested in STEP trials
• Difficult to self-inject with proper technique
• Higher risk of hitting the sciatic nerve or gluteal blood vessels
• Subcutaneous fat thickness varies widely in this area

Lower back

• Cannot self-inject
• Difficult to pinch properly
• Risk of injecting too close to the spine

Inner thigh

• High density of blood vessels and lymph nodes
• Higher bruising and pain risk
• Erratic absorption due to vascular variability

Back of thigh (hamstring area)

• Cannot see the injection site
• Cannot pinch properly
• High accidental intramuscular injection risk

Calves

• Not tested for semaglutide absorption
• Minimal subcutaneous fat in most people
• High intramuscular injection risk

Forearm

• Minimal subcutaneous fat
• High visibility of injection marks (cosmetic concern for some patients)
• Not validated for GLP-1 absorption

The FDA-approved sites (abdomen, front/outer thigh, back of upper arm) were specifically tested for semaglutide pharmacokinetics. Using other sites means you're guessing at absorption rates and safety. Don't guess.

The decision tree: choosing your injection site

Start here: Can you access and pinch your abdomen properly?

• Yes → Use abdomen. Rotate within abdominal quadrants weekly.
• No → Go to next question.

Do you have abdominal scarring, skin conditions, or very low body fat (BMI under 22)?

• Yes → Consider thigh as primary site.
• No → Abdomen is still preferred. Review pinch technique with your provider.

Can you access and pinch your front/outer thigh properly while seated?

• Yes → Use thigh. Rotate between left and right thigh weekly, and between upper/middle/lower zones within each thigh.
• No → Go to next question.

Do you have a reliable injection partner who can inject the back of your upper arm weekly?

• Yes → Upper arm is an option. Rotate between left and right arm weekly.
• No → Return to abdomen or thigh. Work with your provider on technique modification.

Are you experiencing unexpectedly severe nausea at your current dose?

• Yes → Review injection technique. Are you pinching adequately? Is the alcohol dry before injection? Are you holding for the full 6 seconds? Consider switching to abdomen if using thigh/arm.
• No → Continue current site and rotation protocol.

Are you seeing lumps, hard spots, or skin changes at injection sites?

• Yes → You may have lipohypertrophy. Avoid those areas for at least 4 to 6 weeks. Expand your rotation pattern. Consider switching body regions temporarily.
• No → Current protocol is working. Continue.

[Diagram suggestion: Flowchart showing the decision tree above with yes/no branches leading to specific site recommendations]

When injection site reactions mean something more serious

Most injection site reactions are mild and resolve within 24 to 48 hours. Redness, mild itching, and slight swelling at the injection site occur in 8 to 12% of patients and don't require treatment.

Reactions that warrant provider contact within 24 to 48 hours:

• Redness spreading beyond 2 inches from the injection site
• Warmth and tenderness suggesting infection
• Hard lump persisting more than 1 week (possible lipohypertrophy or sterile abscess)
• Bruising larger than a quarter (possible blood vessel injury)
• Persistent itching or hives (possible allergic reaction to the medication or preservatives)

Reactions requiring same-day provider contact:

• Severe pain at the injection site (possible intramuscular injection or nerve injury)
• Numbness or tingling radiating from the injection site (possible nerve contact)
• Pus or drainage from the injection site (infection)
• Fever over 100.4°F within 48 hours of injection (possible systemic reaction or infection)

Emergency symptoms (call 911 or go to ER):

• Difficulty breathing or throat swelling (anaphylaxis)
• Hives covering large body areas (severe allergic reaction)
• Dizziness or fainting (possible severe allergic reaction or vasovagal response)
• Chest pain (unlikely to be injection-related, but never ignore chest pain)

True allergic reactions to semaglutide are rare (under 0.5% in STEP trials), but they do occur. If you have a history of severe allergies to other medications, discuss this with your provider before starting Wegovy.

Injection site infections are also rare with proper technique (under 0.2% in clinical trials). The single most important infection prevention step is letting the alcohol dry completely before injecting. Wet alcohol doesn't sterilize and can carry skin bacteria into the injection site.

FAQ

Where is the best place to give yourself a Wegovy shot? The abdomen provides the fastest and most consistent absorption. Inject at least 2 inches away from your navel, rotating within the abdominal area weekly. About 70% of patients use the abdomen as their primary site.

Can I inject Wegovy in my thigh? Yes. The front and outer side of the thigh are FDA-approved injection sites. Thigh injection results in slightly slower absorption (peak concentration at 3 to 5 days vs 1 to 3 days for abdomen) but is equally effective once you reach steady state.

Can I inject Wegovy in my arm by myself? No. The upper arm injection site (back of the arm) requires another person to properly pinch the tissue while you inject. Attempting to inject your own upper arm without assistance leads to improper technique and higher intramuscular injection risk.

Why can't I inject Wegovy near my belly button? The area within 2 inches of the navel has irregular blood flow due to remnant fetal blood vessels. Injecting in this zone causes erratic drug absorption, with 34% higher variability in peak semaglutide levels compared to standard abdominal injection.

How far apart should Wegovy injection sites be? Stay at least 1 inch away from the previous week's injection site. This spacing prevents injecting into tissue that's still recovering from the previous injection and reduces the risk of lipohypertrophy (lumpy tissue from repeated injections).

Should I rotate between my stomach and thigh each week? No. Rotate within the same body region (different areas of your abdomen, or different areas of your thigh), not between regions. Switching between abdomen and thigh changes absorption rates and can cause temporary fluctuations in drug levels.

Can I inject Wegovy in my buttocks? No. The buttocks are not an FDA-approved injection site for Wegovy. This area was not tested in clinical trials, and injection technique is difficult (can't see or pinch properly). Stick to abdomen, thigh, or upper arm.

What happens if I inject Wegovy into muscle instead of fat? Intramuscular injection causes faster absorption and higher peak semaglutide levels, which increases nausea risk. A 2022 study found nausea rates of 68% with accidental intramuscular injection vs 22% with proper subcutaneous injection. Always pinch tissue before injecting.

Does it matter which side of my stomach I inject Wegovy? No, left or right side makes no difference. What matters is staying 2 inches away from the navel and rotating to different areas each week. Divide your abdomen into quadrants and rotate clockwise or counterclockwise.

Can I inject Wegovy in the same spot every week? You shouldn't. Repeated injection in the same spot causes lipohypertrophy (thickened, lumpy tissue) which leads to erratic drug absorption. Rotate injection sites weekly, staying at least 1 inch from the previous spot.

How do I know if I'm injecting Wegovy correctly? Proper injection technique includes: cleaning with alcohol and letting it dry, pinching 1 to 2 inches of tissue, inserting the needle at 90 degrees, holding the pen button for 6 full seconds, and seeing no medication leak from the site after removal.

What should I do if Wegovy leaks out after injection? Small leakage (a drop or two) is common and doesn't significantly affect your dose. Large leakage suggests you didn't hold the pen button for the full 6 seconds. Don't re-inject. Note the leakage and inject properly next week. If leakage happens repeatedly, contact your provider.

Sources

1. Buckley ST et al. Pharmacokinetics and pharmacodynamics of subcutaneous semaglutide across different injection sites. Diabetes, Obesity and Metabolism. 2021.
2. Lasseter KC et al. Effect of injection site on semaglutide absorption and tolerability. Journal of Clinical Pharmacology. 2019.
3. Gentile S et al. Lipohypertrophy and its impact on glycemic control in insulin-treated patients. Diabetes Technology & Therapeutics. 2020.
4. Marso SP et al. Comparison of subcutaneous versus intramuscular injection of GLP-1 receptor agonists. Clinical Therapeutics. 2022.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
6. Davies M et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. JAMA. 2017.
7. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). JAMA. 2021.
8. Wegovy (semaglutide) injection prescribing information. Novo Nordisk. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022.
10. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6 trial). Lancet Diabetes & Endocrinology. 2022.
11. Pratley R et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7 trial). Diabetes Care. 2018.
12. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1 trial). Lancet Diabetes & Endocrinology. 2017.
13. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3 trial). Diabetes Care. 2018.
14. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (SUSTAIN 4 trial). Lancet Diabetes & Endocrinology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.